A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
Clinical trial NCT03205163 · COMPLETED
Trial details
- NCT number
- NCT03205163
- Sponsor
- Bioverativ, a Sanofi company
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-28
- Primary completion
- 2018-11-12
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.